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Stenotrophomonas maltophilia is a common nosocomial pathogen that causes high
morbidity and mortality. Because of its inherent extended antibiotic resistance,
therapeutic options for S. maltophilia are limited, and sulfamethoxazole/trimethoprim
(SXT) is the only first-line antimicrobial recommended. However, with the spread of
dihydropteroate synthase (sul1 and sul2) genes, global emergence of SXT resistance
has been reported. There is an urgent need to develop a rapid and sensitive but
cost-efficient method to monitor the dissemination of sul genes. In this study, we
developed loop-mediated isothermal amplification (LAMP) assays for sul1 and sul2
using real-time turbidity and hydroxy naphthol blue coloration methods. The assays
could quickly detect sul genes with high sensitivity and specificity. The LAMP detection
limit was 0.74 pg/reaction of extracted genomic DNA for sul1 and 2.6 pg/reaction
for sul2, which were both 10-fold more sensitive than the corresponding traditional
PCR assays. Additionally, the LAMP assays could positively amplify DNA from sul1-
producing strains, but not from the negative controls. We then used the LAMP assays
to investigate the dissemination of sul genes among S. maltophilia isolates from patients
in three hospitals in Beijing, China. Among 450 non-duplicated samples collected
during 2012–2014, 56 (12.4%) strains were SXT-resistant. All these SXT-resistant strains
were positive for sul genes, with 35 (62.5%) carrying sul1, 17 (30.4%) carrying sul2,
and 4 (7.1%) carrying both sul1 and sul2, which indicated that sul genes were the
predominant resistance mechanism. Of 394 SXT-susceptible strains, 16 were also sul-
positive. To provide epidemiological data for the appropriate choice of antimicrobials
for treatment of sul-positive S. maltophilia, we further tested the susceptibility to 18
antimicrobials. Among these, sul-positive strains showed the highest susceptibility to
tetracycline derivatives, especially minocycline (MIC50/MIC90, 0.5/4; susceptibility rate,
95.4%). Ticarcillin-clavulanate and new fluoroquinolones (moxifloxacin and levofloxacin)
also showed some in vitro activity. Apart from these three kinds of antimicrobials, other
agents showed poor activity against sul-positive strains.
Keywords: loop-mediated isothermal amplification, LAMP, Stenotrophomonas maltophilia, dihydropteroate
synthase, sul gene, sulfamethoxazole, minocycline
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INTRODUCTION
Stenotrophomonas maltophilia is the third most common
non-fermentative gram-negative bacillus isolated from
hospitals and has emerged as an important opportunistic
pathogen (Looney et al., 2009). It is associated with a broad
range of serious human infections, including pneumonia,
bloodstream infections, and urinary tract infections, especially in
immunocompromised patients (Looney et al., 2009; Chang
et al., 2015). An increasing incidence and considerable
morbidity have been reported in recent decades (Falagas
et al., 2009; Looney et al., 2009). Since S. maltophilia shows
a high level of intrinsic resistance to most commonly
used antimicrobial agents, including most cephalosporins,
carbapenems, aminoglycosides, and quinolones, its treatment is
extremely difficult. Sulfamethoxazole/trimethoprim (SXT) is the
only first-line antimicrobial recommended for treatment because
of its good antibacterial activity in vitro and low incidence of
resistance (Abbott et al., 2011; Wu et al., 2012; Wei et al., 2015).
Although other mechanisms, such as dfrA and SmeDEF genes,
might influence the minimal inhibitory concentration (MIC),
the sul genes have generally been recognized as the predominant
resistance mechanism (Toleman et al., 2007; Hu et al., 2011).
The sul genes are usually located on mobile genetic elements,
and can mobilize horizontally and vertically, assisted by the
spread of class 1 integrons and insertion sequence common
region (ISCR) elements. The global emergence of SXT resistance
mediated by the dissemination of sul genes has been reported
(Toleman et al., 2007). There is an urgent need to develop a
rapid, simple, and cost-effective assay for the epidemiological
investigation and surveillance of the dissemination of sul
genes, which could provide epidemiological data to guide the
establishment of infection control measures and the choice of
initial antimicrobials. Loop-mediated isothermal amplification
(LAMP) is a novel DNA amplification method. It was first
developed in the year 2000 and can efficiently and specifically
amplify DNA under isothermic conditions within 60 min using
Bst DNA polymerase (Notomi et al., 2000; Dong et al., 2015a).
The only requirement to perform LAMP assays is having access
to a constant-temperature apparatus. Moreover, by adding
hydroxy naphthol blue (HNB), the results can be evaluated
by the naked eye, thus avoiding the process of agarose gel
electrophoresis that is required for traditional PCR. LAMP assays
have been used for the rapid diagnosis of infectious diseases and
the surveillance of epidemics of bacteria, viruses, and parasites
(Sun et al., 2010; Wang et al., 2011; Soo et al., 2013). Recently,
the technique has also been used for the surveillance of genes
encoding various carbapenemase enzymes (Qi et al., 2012;
Nakano et al., 2015; Yamamoto et al., 2015; Kim et al., 2016), but
there have been no reports on the use of LAMP for the detection
of SXT-resistance genes.
The objectives of this study were to establish a rapid,
simple, and cost-effective assay for the detection of sul genes
in S. maltophilia and to investigate the dissemination and
antimicrobial susceptibility of S. maltophilia carrying sul genes.
These data are essential to guide the establishment of infection
control measures and the choice of an appropriate initial
antibacterial agent. First, we developed LAMP assays for the
detection of sul1 and sul2 and confirmed their specificity and
sensitivity using two different detection methods, namely sample
turbidity and HNB coloration. We then used the LAMP assays to
study the dissemination of sul genes in three hospitals in Beijing,
China during 2012–2014. Finally, the susceptibility of the sul-
positive S. maltophilia strains to 18 commonly used antimicrobial
agents was investigated.
MATERIALS AND METHODS
Bacterial Isolation and Identification
In this study, during 2012–2014, 450 non-duplicated clinical
S. maltophilia isolates were collected from hospitalized patients
in the Chinese PLA General Hospital, Peking Union Medical
College Hospital, and Air Force General Hospital in Beijing,
China. Bacterial species identification was performed using a
Vitek R© II bacterial identification system (bioMérieux, Marcy-
l’Étoile, France) and further confirmed by species-specific PCR
(Whitby et al., 2000). Three sul1 (X2, P121, and K106) and
sul2 (X133, P57, and K14) positive control DNAs were used in
the establishment of the LAMP assays and were confirmed to
carry sul genes by PCR and sequencing of the PCR products.
S. maltophilia ATCC 13637, K279a, and P129 were used as
negative controls for estimating the specificity of the LAMP
assays. Whole genome sequencing of these strains has been
performed and they were confirmed to carry genes encoding
multidrug-eﬄux pumps, β-lactamases, and aminoglycoside-
modifying enzymes, but they did not carry sul genes (Crossman
et al., 2008; Davenport et al., 2014).
The research protocol was approved by the Ethics Committee
of Chinese PLA General Hospital, Peking Union Medical College
Hospital, and Air Force General Hospital, and written informed
consent was obtained from patients. Our research protocol did
not affect patients’ health, safety, or privacy.
PCR Detection of sul Genes
Whole genomic DNA (including plasmid DNA) was extracted
using the protocol described by a previous study (Yang et al.,
2014). The bacterial strains were cultured in brain–heart infusion
broth at 37◦C. Genomic DNA was extracted using a Wizard R©
Genomic DNA Purification Kit (Promega, Madison, WI, USA)
according to the manufacturer’s recommended protocol. The
extracted DNA was used as a template in the LAMP and PCR
reactions.
To compare the sensitivity of LAMP assays and traditional
PCR, sul1 detection was performed using the PCR primers shown
in Table 1. The target products were 250 bp for sul1 and 276 bp
for sul2. The PCR cycling parameters were: initial PCR activation,
95◦C for 5 min; amplification, 30 cycles of 95◦C for 30 s, 55◦C
for 30 s, and 72◦C for 30 s; final extension step, 72◦C for
10 min. A 25-µl reaction volume was used, and the products were
separated by 1% (w/v) agarose (Amresco, Solon, OH, USA) gel
electrophoresis and stained with ethidium bromide. Images were
documented with a Gel DocTM EQ imaging system (Bio-Rad,
Hercules, CA, USA).
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TABLE 1 | Primers used for the specific amplification of the sul1 and sul2 genes.
Target gene Reaction type Primer Sequence (5′–3′) Location
sul1 PCR SUL1-F GCTATTGGTCTCGGTGTCGC 612–631
SUL1-B GCATGATCTAACCCTCGGTCT 836–816
sul2 PCR SUL2-F TTTCGGCATCGTCAACATAA 21–40
SUL2-B CCACGCGACAAGGCATA 296–280
sul1 LAMP Sul1-33F3 GGCCGATGAGATCAGACGT 174–192
Sul1-33B3 TCCCGCTGCGCTGAGT 392–377
Sul1-33FIP TGGGTTTCCGGTTGGAAGCTGT, CCGCTCTTAGACGCCCT 266–245, 199–215
Sul1-33BIP TCCAAGGATTTCCTGACCCTGC, GCATAACCACCAGCCTGCA 308–329, 376–358
Sul1-33LF AAACACGGTGCATCTGATCG 238–219
Sul1-33LB GCTCTATCCCGATATTGCTGAGG 330–352
sul2 LAMP Sul2-121F3 ACCCGCTGGCGACATC 423–438
Sul2-121B3 AGAAGCACCGGCAAATCG 623–606
Sul2-121FIP TGATACCGGCACCCGTCAGC, ATGGATCACATTGCGGCGTT 499–480, 439–458
Sul2-121BIP CTTGATCCCGGCATGGGGTTTT, GCCGCAATTCATCGAACCG 517–538, 598–580
Sul2-121LF CGATGCGCGCGTCAAAG 475–459
Sul2-121LB GGCTGCTCCCGAAACCT 546–562
The sequences CP011493 (80815–81654) and CP009257 (2540172–2540987) obtained from the NCBI GenBank database were used for the design of sul1-specific
and sul2-specific PCR and LAMP primers, respectively. F3, forward outer primer; B3, backward outer primer; FIP, forward internal primer; BIP, backward internal primer;
LF, loop forward primer; LB, loop backward primer.
LAMP Reaction
The sequences CP011493 (80815–81654) and CP009257
(2540172–2540987) obtained from the NCBI GenBank database
were used for the design of sul1-specific and sul2-specific PCR
and LAMP primers, respectively. The primers were designed
and analyzed by PrimerExplorer software1. The sequences and
locations of primers for sul1 and sul2 are both shown in Table 1.
The LAMP reactions were performed in a final volume of 25µl
containing 12.5 µl reaction mixture, 1 µl Bst DNA polymerase,
and 2 µl template using the Loopamp DNA Amplification Kit
(Loopamp DNA Amplification Kit; Eiken Chemical, Co., Ltd,
Tochigi, Japan) for real-time turbidimetry or with the further
addition of 1 µl HNB solution (Eiken Chemical, Co., Ltd) for
visual detection. Primers were used at the concentrations of
1.6 µM for the forward internal primer and backward internal
primer, 0.8 µM for the loop forward primer and loop backward
primer, and 0.2 µM for the forward outer primer and backward
outer primer. The reactions were performed in the reaction tubes
(Eiken Chemical, Co., Ltd) for 60 min at 65◦C.
Two different methods, namely sample turbidity and HNB
coloration, were used to detect the LAMP products. Real-time
changes in turbidity were monitored by spectrophotometric
analysis by recording the optical density (650 nm) every 6 s with a
Loopamp Realtime Turbidimeter (LA-320c; Eiken Chemical, Co.,
Ltd). For direct visual detection, 1 µl of HNB detection reagent
was added to the reaction. The amount of DNA template used
in the LAMP reaction mixture was equal to that used in PCR
reactions. Each experiment was performed at least three times.
Antimicrobial Susceptibility Testing
Eighteen clinically used antibacterial agents were tested in our
study, as follows: SXT, ceftazidime, minocycline, levofloxacin,
1http://primerexplorer.jp/e/
chloramphenicol, ticarcillin/clavulanate, tigecycline, doxycycline,
moxifloxacin, cefepime, cefoperazone/sulbactam, meropenem,
amikacin, colistin, fosfomycin, aztreonam, azithromycin,
and rifampicin. Tigecycline was obtained from Wyeth
Pharmaceutical (Wyeth Pharmaceutical, Philadelphia, PA,
USA); moxifloxacin was obtained from Bayer Healthcare (Bayer
Pharma, Wuppertal, AG, Germany); Colistin was purchased
from Sigma-Aldrich (St. Louis, MO, USA); other antimicrobial
agents were purchased from the National Institute for the Control
of Pharmaceutical and Biological Products (NICPBP, Beijing,
China). The antimicrobial powders were used to prepare stock
solutions, as described by the Clinical and Laboratory Standards
Institute (CLSI, 2015). MICs of the sul-positive strains were
determined for each isolate by the Mueller–Hinton agar (Difco,
Franklin Lakes, NJ, USA) macrodilution method. Pseudomonas
aeruginosa ATCC 27853, Staphylococcus aureus ATCC 29213,
and Escherichia coli ATCC 25922 were used as quality control
strains to ensure the accuracy and reliability of the assays.
Interpretive breakpoints for susceptibility are available only for
SXT, ceftazidime, minocycline, levofloxacin, chloramphenicol,
and ticarcillin/clavulanate (CLSI, 2015). Other antimicrobial
agents with no published breakpoint criteria for S. maltophilia
were interpreted with reference to those for Acinetobacter spp. or
Enterobacteriaceae published by CLSI (2015) (Table 3).
RESULTS
Establishment of LAMP Assays for the
Detection of sul1 and sul2
The sul1-specific and sul2-specific LAMP primers were designed
and analyzed using PrimerExplorer software (Table 1). To
compare the detection limit of the LAMP method with that of
the conventional PCR method, genomic DNA was extracted from
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S. maltophilia X2 and serially diluted 10 times from 37.0 ng/µL
to 3.7 fg/µL. As shown in Figure 1, the detection limits of the
real-time turbidity and HNB methods were 0.74 pg/reaction of
extracted whole genomic DNA, 10-fold more sensitive than that
of the PCR assay (7.4 pg/reaction) (Figure 1). Similarly, the
detection limit of LAMP specific to sul2 was 2.6 pg/reaction,
which is 10 times more sensitive than that obtained for the
conventional PCR method (Figure 2).
The specificity of the LAMP assay for detecting sul1
was evaluated using X2, P121, and K106 carrying sul1 as
positive controls, S. maltophilia ATCC 13637, K279a, and
P129 as negative controls, and distilled water as blank
control. As shown in Figure 3, both methods positively
amplified DNA from sul1-producing strains, but not from
the negative and blank controls. The results showed that
the assay was highly specific for detecting sul1. The same
results were observed for the developed sul2 LAMP assay
(Figure 4).
Dissemination of sul Genes in
S. maltophilia
During 2012–2014, 450 non-duplicated S. maltophilia strains
were collected in our study, and 56 (12.4%) strains were resistant
to SXT. As shown in Table 2, all these 56 SXT-resistant strains
were tested positive for sul genes, among which 35 (62.5) strains
carried sul1, 17 (30.4%) strains carried sul2, and 4 (7.1%) strains
carried both sul1 and sul2. Among 394 SXT-susceptible strains,
16 (4.1%) carried sul genes.
Antimicrobial Susceptibility of
sul-Positive S. maltophilia
Among 18 clinically used antimicrobials, the susceptibility
rates of S. maltophilia were 95.4% for minocycline, 68.1% for
doxycycline and tigecycline, 50.0% and 59.7% for levofloxacin
and moxifloxacin, respectively, and 69.4% for ticarcillin-
clavulanate. The susceptibility rates for 12 other antimicrobial
FIGURE 1 | Comparison of the sensitivities of LAMP and conventional PCR assays for detecting sul1 in Stenotrophomonas maltophilia. (A) Turbidity
was monitored every 6 s using a Loopamp Realtime Turbidimeter with detection at 650 nm. The reaction was performed at 65◦C. (B) The results were visualized by
adding hydroxy naphthol blue (HNB) to the reaction mixture before the reaction. (C) PCR products were separated by 1% (w/v) agarose gel electrophoresis and
stained with ethidium bromide. (1) 74.0 ng; (2) 7.4 ng; (3) 0.74 ng; (4) 74.0 pg; (5) 7.4 pg; (6) 0.74 pg; (7) 74.0 fg; (8) 7.4 fg; (9) blank control (double-distilled water).
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FIGURE 2 | Comparison of the sensitivities of LAMP and conventional PCR assays for detecting sul2 in S. maltophilia. (A) Turbidity was monitored every
6 s using a Loopamp Realtime Turbidimeter with detection at 650 nm. The reaction was performed at 65◦C. (B) The results were visualized by adding HNB to the
reaction mixture before the reaction. (C) PCR products were separated by 1% (w/v) agarose gel electrophoresis and stained with ethidium bromide. (1) 26.0 ng; (2)
2.6 ng; (3) 0.26 ng; (4) 26.0 pg; (5) 2.6 pg; (6) 0.26 pg; (7) 26.0 fg; (8) blank control (double-distilled water).
agents were less than 50%, while for the agents meropenem,
amikacin, colistin, ceftazidime, chloramphenicol, aztreonam,
sulfamethoxazole/trimethoprim, azithromycin, and rifampicin,
S. maltophilia had resistance rates exceeding 70% (Table 3).
DISCUSSION
Stenotrophomonas maltophilia is an opportunistic pathogen,
mainly causing pneumonia and bloodstream infections in
immunocompromised patients, with high morbidity and
mortality (Falagas et al., 2009; Looney et al., 2009; Chang et al.,
2015). Because of its intrinsic and acquired resistance to most
commonly clinical used antibiotics, its treatment is extremely
difficult, and SXT is the only first-line drug recommended
(Looney et al., 2009; Chang et al., 2015), with an overall
susceptibility rate of higher than 90% (Abbott et al., 2011; Wu
et al., 2012; Chang et al., 2015; Wei et al., 2015). Resistance to
SXT in S. maltophilia will lead to more treatment failure and
higher mortality, and the global emergence of an increasing
tendency toward SXT resistance mediated by the dissemination
of sul genes has been reported. Surveillance of the dissemination
of sul genes by rapid and cost-efficient LAMP assays could
contribute to the control of SXT resistance and the reduction
of S. maltophilia infection incidence. In the current study, we
designed primers specific for both sul1 and sul2 for use in LAMP
assays to monitor the prevalence of sul genes among clinical
isolates of S. maltophilia. The LAMP detection method has
several advantages over traditional PCR as a tool for use in
epidemiological surveys. First, LAMP is generally less time- and
labor-intensive, and it proceeds under an isothermal condition
within 60 min (Notomi et al., 2000; Dong et al., 2015a; Li et al.,
2015). Second, LAMP is more cost-efficient than conventional
PCR, since it only requires access to a constant-temperature
apparatus, such as a common laboratory water bath. Third,
LAMP is more sensitive than traditional PCR. The LAMP
detection limit was 0.74 pg/reaction for sul1 and 2.6 pg/reaction
for sul2, which were both 10-fold more sensitive than the
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FIGURE 3 | Specificity of the LAMP reaction for detecting sul1 in S. maltophilia. (A) Turbidity was monitored every 6 s using a Loopamp Realtime
Turbidimeter with detection at 650 nm. The reaction was performed at 65◦C. (B) The results were visualized by adding HNB to the reaction mixture before the
reaction. (1) X2 (positive control for sul1 from Peking Union Medical College Hospital); (2) P121 (positive control for sul1 from Chinese PLA General Hospital); (3) K106
(positive control for sul1 from Chinese PLA General Hospital); (4) S. maltophilia K279a; (5) S. maltophilia ATCC 13637; (6) P129 (negative control for sul from Chinese
PLA General Hospital, confirmed by genome sequencing); (7) double-distilled water.
corresponding traditional PCR assays. Despite having a higher
sensitivity than traditional PCR, the LAMP assays remained
specific, and the negative controls used for estimating the
specificity were all negative in the LAMP assays. Moreover,
after adding HNB, the reaction results could be evaluated by
the naked eye, which not only avoids the process of agarose gel
electrophoresis that is required with conventional PCR methods,
but also reduces the chance of cross-contamination (Liu et al.,
2012; Solanki et al., 2013; Yang et al., 2014; Dong et al., 2015b).
Using these LAMP assays, we surveyed the prevalence of
sul genes among clinical isolates of S. maltophilia in three
hospitals in Beijing. We isolated 56 SXT-resistant strains and
found that they all carried sul genes. The results indicated that
the carriage of sul1 and/or sul2 might be the predominant
mechanism of SXT resistance in Beijing, China, as has been
reported from other domestic and international surveys (Chang
et al., 2007; Toleman et al., 2007; Hu et al., 2011; Chung et al.,
2015; Kaur et al., 2015). We also detected both sul1 and sul2
in some SXT-susceptible S. maltophilia strains. Recent studies
also have reported the detection of sul1 and sul2 in SXT-
susceptible S. maltophilia isolates (Chang et al., 2007; Hu et al.,
2016). Therefore, the phenotypic breakpoints are not reliable for
genotypic identification. In addition, SXT resistance breakpoints
are established from a clinical efficacy perspective that also
considers the dosage, pharmacokinetics/pharmacodynamics, and
clinical trials. SXT treatment might fail for these strains, since
resistance could emerge during treatment through the up-
regulation of sul genes expression.
There are limited antimicrobial options for infection due to S.
maltophilia because of its extensive resistance to most antibiotics.
The occurrence of acquired resistance to SXT mediated by the
dissemination of sul genes increases the difficulty of selecting
an appropriate choice for treatment. To provide epidemiological
data for the choice of appropriate antimicrobial agents for the
treatment of sul-positive S. maltophilia, we further tested their
susceptibility to 18 clinically used antimicrobials. In previous
studies, ceftazidime and ticarcillin/clavulanate were reported as
the most effective β-lactam drugs against S. maltophilia (Chang
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FIGURE 4 | Specificity of the LAMP reaction for detecting sul2 in S. maltophilia. (A) Turbidity was monitored every 6 s using a Loopamp Realtime
Turbidimeter with detection at 650 nm. The reaction was performed at 65◦C. (B) The results were visualized by adding HNB to the reaction mixture before the
reaction. (1) X133 (positive control for sul2 from Peking Union Medical College Hospital); (2) P57 (positive control for sul2 from Chinese PLA General Hospital); (3) K14
(positive control for sul2 from Chinese PLA General Hospital); (4) S. maltophilia K279a; (5) S. maltophilia ATCC 13637; (6) P129 (negative control for sul from Chinese
PLA General Hospital, confirmed by genome sequencing); (7) double-distilled water.
et al., 2015). However, only 23% of sul-positive strains remained
susceptible to ceftazidime in our study, and ceftazidime seemed
not to be a good choice due to exhibiting poor in vitro activity.
Nearly 70% of sul-positive S. maltophilia strains remained
susceptible to ticarcillin/clavulanate, and ticarcillin/clavulanate
seemed to be a good choice for the treatment of sul-positive
strains. However, the recommendation for the use of ticarcillin-
clavulanate should be made with caution, since the L1/L2
β-lactamases carried by S. maltophilia have strong activity and
together can inactivate nearly all β-lactam antibiotics.
New fluoroquinolones, such as moxifloxacin and levofloxacin,
have been reported to show good in vitro activity and could be
alternative therapeutic options against S. maltophilia (Valdezate
et al., 1999; Nicodemo and Paez, 2007; Looney et al., 2009).
Fluoroquinolones are now popular alternatives because of
their lesser side effects compared to those of SXT. A clinical
comparison of SXT and levofloxacin showed that their overall
microbiological cure and clinical success rates showed no
statistically significant difference, but the rate of adverse events
TABLE 2 | Detection rates of sul genes in Stenotrophomonas maltophilia
isolated from China during 2012–2014.
sul gene(s) Detection rate (%)
SR-SMA (n = 56) SS-SMA (n = 394) Total (n = 450)
sul1 35 (62.5) 12 (3.0%) 47 (10.4)
sul2 17 (30.4) 4 (1.0) 21 (4.7)
sul1+sul2 4 (7.1) 0 4 (0.9)
total 56 (100) 16 (4.1) 72 (16)
SR-SMA, sulfamethoxazole/trimethoprim-resistant S. maltophilia; SS-SMA,
sulfamethoxazole/trimethoprim-susceptible S. maltophilia.
was significantly lower in the levofloxacin group than in the
SXT group (Cho et al., 2014; Wang et al., 2014). However, in
our study, nearly 50% of sul-positive S. maltophilia strains were
non-susceptible to moxifloxacin and levofloxacin. Moreover,
it has been reported that the overuse of fluoroquinolones
worldwide has resulted in a higher resistance rate among
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TABLE 3 | In vitro susceptibility of 72 sul-positive S. maltophilia strains to
18 clinically used antimicrobials.
Antimicrobial
agents
MIC (mg/L) Susceptibility (%)
Range MIC50 MIC90 S I R
SXT 19/1 to >304/16 152/8 >304/16 22.2 77.8
MIN 0.25–16 0.5 4 95.4 2.8 1.4
LEV 0.5–32 2 32 50 6.9 43.1
CHL 2 to >64 64 >64 5.6 12.5 81.9
CET 2 to >64 64 >64 23.6 5.6 70.8
T-C 1 to >128 8 128 69.4 13.9 16.7
TIG† 0.5–32 2 8 68.1 12.5 19.4
DOX∗ 1–64 4 16 68.1 15.3 16.7
MOX§ 0.25–32 2 16 59.7 6.9 33.3
CEP† 2–128 32 64 18.1 81.9
C-S† 4 to >256 32 128 40.3 18.1 41.7
MEP∗ 32 to >32 >32 >32 0 0 100
AMK∗ 32 to >64 >64 >64 0 2.8 97.2
COL∗ 1 to >64 16 >64 12.5 87.5
FOS† 32 to >256 128 256 22.2 47.2 30.6
AZT† 16 to >32 >32 >32 0 0 100
AZM† 32 to >64 64 >64 0 0 100
RFP# 2–64 16 32 0 0 100
SXT, sulfamethoxazole/trimethoprim; MIN, minocycline; LEV, levofloxacin;
CHL, chloramphenicol; CET, ceftazidime; T-C, ticarcillin-clavulanate; TIG,
tigecycline; DOX, doxycycline; MOX, moxifloxacin; CEP, cefepime; C-S,
cefoperazone/sulbactam; MEP, meropenem; AMK, amikacin; COL, colistin; FOS,
fosfomycin; AZT, aztreonam; AZM, azithromycin; RFP, rifampin. ∗MIC breakpoint
criteria of these antimicrobials for S. maltophilia refer to susceptible breakpoint
criteria for Acinetobacter spp. published by CLSI (2015); †MIC breakpoint criteria
of these antimicrobials for S. maltophilia refer to susceptible breakpoint criteria for
Enterobacteriaceae published by CLSI (2015); § MIC breakpoint criteria of MOX for
S. maltophilia refer to susceptible breakpoint criteria for anaerobes published by
CLSI (2015); #MIC breakpoint criteria of RFP for S. maltophilia refer to susceptible
breakpoint criteria for Staphylococcus spp. published by CLSI (2015).
many pathogenic bacteria, including S. maltophilia (Chang
et al., 2014; Pien et al., 2015). Therefore, it would be prudent
to use them as initial empirical antibiotics for sul-positive
strains.
Tetracycline derivatives, such as tigecycline, minocycline, and
doxycycline, have been reported to be the most active agents
against S. maltophilia other than SXT, even in patients with
cystic fibrosis. Global surveillance studies have reported that
minocycline was found to be significantly more active than
other tetracyclines, and the susceptibility rate of S. maltophilia
to minocycline exceeded 97% across all geographic regions
(Gales et al., 2008; Chen et al., 2012; Milne and Gould,
2012; Wu et al., 2012; Chung et al., 2013; Castanheira et al.,
2014; Sader et al., 2014). The results of our study agreed
with the aforementioned observations, and the tetracycline
derivatives we tested, including minocycline, doxycycline, and
tigecycline, all showed good in vitro activity against clinical
isolates of sul-negative S. maltophilia. Minocycline showed a
particularly high in vitro activity, with S. maltophilia showing
a susceptibility rate of 95% against this drug. Tetracycline
derivatives might be an appropriate therapeutic option for these
sul-positive drugs, based on their excellent in vitro activities.
Ten other agents, including colistin, aztreonam, meropenem,
amikacin, azithromycin, fosfomycin, and rifampicin, showed
little activity against sul-positive S. maltophilia strains, and
they should not be recommended for use as monotherapy
to treat these strains. Epidemiological data might contribute
to guiding the choice of an appropriate initial antimicrobial
for the treatment of sul-positive S. maltophilia and reducing
the frequency of treatment failures. However, choosing an
initial antimicrobial agent by referring to epidemiological
data alone is not always adequate, and making more precise
treatment choices based on antimicrobial susceptibility testing is
encouraged.
CONCLUSION
We have developed rapid, simple, and cost-efficient LAMP assays
for the detection of the SXT resistance genes sul1 and sul2 with
high sensitivity and specificity. These assays could contribute
to the epidemiological investigation and surveillance of the
dissemination of sul genes, which could provide epidemiological
data to guide the establishment of infection control measures
and the choice of initial antimicrobials. Using these methods,
450 non-duplicated S. maltophilia strains isolated from three
hospitals in Beijing, China were screened, and 72 (16.0%) of
these strains tested positive for sul genes. These sul-positive
strains showed poor susceptibility to most clinically used
antimicrobials apart from tetracycline derivatives, ticarcillin-
clavulanate, moxifloxacin, and levofloxacin. The developed
LAMP assays provide a useful tool for the surveillance of sul genes
among clinical S. maltophilia strains, since these assays are more
sensitive, faster, and more cost-efficient than the conventional
PCR method.
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